#For patients
Written for adults considering a peptide as part of their health management.
Ozempic in Pro-Eating-Disorder Communities
A 2026 study finds Ozempic, a semaglutide brand, is normalized more than warned against in a pro-eating-disorder community on X.
CJC-1295 and Ipamorelin, Explained
CJC-1295 and ipamorelin are unapproved growth-hormone-axis peptides. Here is what the evidence shows, and why we will not give you a starting dose.
What is GEP44? A GLP-1/PYY explainer
GEP44 is an investigational peptide that pairs GLP-1 with peptide YY signalling to test whether weight loss can come with fewer GI side effects.
How chemists test what's in GLP-1 drugs
A new peer-reviewed method identifies nine GLP-1 drugs at once. Here is why that kind of identity testing matters right now.
Retatrutide and gallbladder disease risk
Retatrutide is an investigational GLP-1, GIP and glucagon triple agonist. Here is what the trial and label data show about gallbladder risk.
Compounded tirzepatide with B6 explained
Compounded tirzepatide, including preparations with added vitamin B6, is not the licensed medicine. Here is what is documented and what is not.
How GLP-1 weight loss drugs really differ
Novo's CEO says patients want optionality. Here is what the approved labels and the single head-to-head trial say really separates these drugs.
GLP-1 gastroparesis symptoms and the gaps
A 2026 systematic review found only 12 published case reports of GLP-1 gastroparesis. Here is what they showed, and what they cannot tell you.
GLP-1 drugs at longevity clinics
Longevity and aesthetic clinics prescribe semaglutide and tirzepatide off-label. Here is what the labels cover, and where the ageing evidence stops.
Peptide cycles per year: no number exists
Cycle lengths come from a few small trials. Cycle counts come from nowhere, because no study has tested repeating a peptide course across a year.
Beyond weight loss: GLP-1 organ outcomes
A JACC editorial reframes GLP-1 drugs as cardiometabolic medicines. The SELECT, FLOW and SOUL trials, and the approved labels, already point that way.
Do GLP-1 drugs cause throat symptoms?
A 2026 Laryngoscope cohort ties GLP-1 drugs to cough, globus and voice change. Here is what an association study can and cannot show.